MycobacteriologyUse of several immunological markers to model the probability of active tuberculosis
Section snippets
Acknowledgments
The authors are grateful to all the patients, nurses (in particular Sara Pantanella, Daniela Milordo, Emanuela Ercoli, Giuliana Rialti, Immacolata Mauceri) and physicians who helped to perform this study. We are deeply grateful to Ms Andrea Baker (INMI, Rome, Italy) and Dr Ilaria Pepponi for the editing. The study was supported by grants from the Italian Ministry of Health: “Ricerca Corrente” and a grant from the European Union: HEALTH-F3-2009-241642 and EC FP7 NEWTBVAC (contract no.
References (17)
- et al.
Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test
Lancet Infect Dis
(2013) - et al.
Assessment of CD27 expression as a tool for active and latent tuberculosis diagnosis
J Infect
(2015) - et al.
IFNgamma/TNFalpha specific-cells and effector memory phenotype associate with active tuberculosis
J Infect
(2013) - et al.
Assessment of the novel T-cell activation marker-tuberculosis assay for diagnosis of active tuberculosis in children: a prospective proof-of-concept study
Lancet Infect Dis
(2014) - et al.
Biomarkers on patient T cells diagnose active tuberculosis and monitor treatment response
J Clin Invest
(2015) - et al.
Functional capacity of Mycobacterium tuberculosis-specific T cell responses in humans is associated with mycobacterial load
J Immunol
(2011) - et al.
Performance of the tuberculin skin test andinterferon-γ release assays: an update on the accuracy, cutoff stratification, and new potential immune-based approaches
J Rheumatol Suppl.
(2014) - et al.
Dominant TNF-alpha+ Mycobacterium tuberculosis-specific CD4+ T cell responses discriminate between latent infection and active disease
Nat Med
(2011)
Cited by (17)
Prospective evaluation of host biomarkers other than interferon gamma in QuantiFERON Plus supernatants as candidates for the diagnosis of tuberculosis in symptomatic individuals
2019, Journal of InfectionCitation Excerpt :Our goal was to evaluate the performance of biomarkers in diagnosing active TB, regardless of whether individuals presenting with symptoms were latently infected or not, as this study was conducted in a high burden setting. As observed in previous studies, combinations between multiple host biomarkers performed better in the diagnosis of TB disease,26,42,43 with a different optimal, and smaller biosignature obtained if only HIV uninfected participants were considered. We were not sufficiently powered to perform a detailed analysis of the influence of HIV infection on the biomarkers as only 14 of the study participants, and only two out of the 69 individuals in whom TB was ruled out (3% of the ORD group) and 7 out of the 35 TB patients (20%) were infected with HIV.
Biomarkers distinguish HBeAg seroconverted from non-converted individuals in chronic hepatitis B patients treated with a therapeutic vaccine
2018, CytokineCitation Excerpt :Analysis of the combined contribution of proinflammatory, inflammatory, anti-inflammatory and chemo-attracting factors is required. Due to the complex interactions in these networks, a single change in cytokine/chemokine may be insufficient to reveal the complete immune status of patients [16]. To circumvent this, we have adopted a Boolean modeling approach using multi-cytokines-chemokines as biomarkers to characterize signatures of patients who subsequently responded or did not respond to the YIC immunotherapy.
First characterization of the CD4 and CD8 T-cell responses to QuantiFERON-TB Plus
2016, Journal of InfectionCitation Excerpt :Following an incubation of 16–24 h, the ICS was performed. As previously described,14,34–36 PBMC were stained with anti-CD4 peridinin chlorophylprotein (PerCp)-Cy5.5 conjugate, anti-CD8 allophycocyanin (APC)-H7 conjugate, anti-CD3 Horizon V500 conjugate and anti-IFN-γ Pacific Blue (PB) conjugate (all from BD Bioscences). The Mtb-specific T-cell response was characterized evaluating the frequencies of IFN-γ CD4 and IFN-γ CD8 T cells (Fig. 1).
Mycobacterium tuberculosis Immune Response in Patients With Immune-Mediated Inflammatory Disease
2021, Frontiers in Immunology